{Reference Type}: Randomized Controlled Trial
{Title}: Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose study.
{Author}: Veverka KA;Thng STG;Silverberg JI;Armstrong AW;Menezes J;Kaoukhov A;Blauvelt A;
{Journal}: J Am Acad Dermatol
{Volume}: 90
{Issue}: 3
{Year}: 2024 Mar 20
{Factor}: 15.487
{DOI}: 10.1016/j.jaad.2023.10.026
{Abstract}: <B>BACKGROUND: </B>Eblasakimab, an interleukin (IL)-13 receptor α1 antagonist, blocks IL-4 and IL-13 signaling through the type 2 receptor.<BR><B>OBJECTIVE: </B>The safety and efficacy of eblasakimab was evaluated in adults with moderate-to-severe atopic dermatitis (AD).<BR><B>METHODS: </B>In this phase 1b randomized, double-blinded study, 52 patients with moderate-to-severe AD received weekly subcutaneous injections of eblasakimab 200, 400, or 600 mg, or placebo for 8 weeks. Primary outcome was the incidence of treatment-emergent adverse events. Secondary outcomes included percentage change in the Eczema Area and Severity Index from baseline; Eczema Area and Severity Index improvement of at least 50%, 75%, or 90% from baseline; and percentage change in the peak-pruritus numeric rating scale score from baseline.<BR><B>RESULTS: </B>Treatment-emergent adverse events were reported in 47% placebo and 71% eblasakimab patients; most were considered mild or moderate and did not lead to study discontinuation. At week 8 eblasakimab 600 mg showed statistically significant improvement in mean percentage change in Eczema Area and Severity Index versus placebo (-65% vs -27%, P = .014). Other key secondary physician- and patient-reported end points were met.<BR><B>CONCLUSIONS: </B>Longer studies are required to confirm eblasakimab safety and efficacy in AD patients.<BR><B>CONCLUSIONS: </B>Treatment of adults with moderate-to-severe AD with eblasakimab was well-tolerated and associated with significant clinical improvements versus placebo.